Dobutamine

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina

Retrieved on: 
Dimanche, novembre 12, 2023
Safety, Incidence, Ischemia, Patient, Dobutamine, Glucose, MRCP, Ex-gay movement, Angina, Quality of life, Moyamoya disease, Professor, Facial muscles, Medical imaging, Pharmaceutical industry

BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing innovative therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced positive topline results from the randomized, double-blind, placebo-controlled Phase 2 IMPROVE-ISCHEMIA trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation (pFOX) inhibitor, in patients with chronic stable angina.

Key Points: 
  • Treatment with ninerafaxstat was well tolerated and no safety signals were observed.
  • At 8-weeks, treatment with ninerafaxstat demonstrated clinically and statistically significant improvements in dobutamine stress-induced ischemic left ventricular (LV) wall motion abnormalities.
  • This robust anti-ischemic effect was not dependent on changes in myocardial blood flow, consistent with a direct, metabolic mechanism of action of ninerafaxstat targeting the cardiomyocyte.
  • “The randomized, placebo-controlled IMPROVE-ISCHEMIA trial provides detailed insights into the anti-ischemic effects of ninerafaxstat in symptomatic patients with stable angina," said Juhani Knuuti, M.D., Ph.D., Professor and Director of Turku PET Centre in Turku, Finland and chief investigator of the IMPROVE-ISCHEMIA trial.

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
Jeudi, décembre 7, 2023
Health, Neurology, General Health, Research, Pharmaceutical, Science, COMT, Medicine, Capsule, Sleep, Aggression, BIAL, Brain, Behavior, NYSE, Hormone, Senior, Food, Parkinson's disease, Eating, Movement, Gambling, Liver, PD, Delusion, Hallucination, Constipation, Sleep disorder, Patient, Multimedia, Dopamine, Dobutamine, Carbidopa, Behavior informatics, FDA, Isocarboxazid, Isoprenaline, Catecholamine, Vitamin, Partnership, Norepinephrine, Carbidopa/levodopa, Adrenaline, L-DOPA, Phenelzine, Mouth, Hearing, Physician, Neoplasm, Dyskinesia, Medication, Somnolence, Accident, Dizziness, Tranylcypromine, Weight loss, Psychosis, Pharmaceutical industry, Birth control, S.A, Amneal Pharmaceuticals, LD

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

Brooke Army Medical Center (BAMC) Establishes Clinical Utility of Seraph 100 for Critically Ill Patients Suffering from Septic Shock Caused by Multiple Pathogens Including Candida

Retrieved on: 
Mardi, mai 2, 2023
FDA, COVID-19, Pharmaceutical, Professional Services, General Health, Medical Devices, Infectious Diseases, Hospitals, Clinical Trials, Science, Biotechnology, Data Analytics, Other Science, Health, Research, Blood pressure, Infection, BAMC, Hospice and palliative medicine, Partnership, SOFA, SARS-CoV-2, Public, Candidiasis, Extracorporeal membrane oxygenation, Survival, Angiotensin, ECMO, Army Medical School, Brooke Army Medical Center, Septic shock, Fungus, CDC, Hospital, Patient, Mortality, Bacteria, Dobutamine, SOFA score, Death, Virus, Auris, Pharmaceutical industry, Norepinephrine, Seraph

Brooke Army Medical Center published positive results for critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter.

Key Points: 
  • Brooke Army Medical Center published positive results for critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter.
  • CDC has issued a recent warning considering the threat of Candida auris to public health, so emerging evidence of Seraph 100 successful treatment of Candida infections is timely.
  • The Seraph 100 is an extracorporeal blood filter used to remove pathogens from the bloodstream of patients who are critically ill from infections that cause septic shock, i.e., the reduced blood pressure that often leads to cascading illness and death.
  • ExThera Medical previously confirmed that Seraph 100 is effective at removing many different bacteria, viruses and fungi, including the often-deadly Candida auris strain.

Nacuity Pharmaceuticals Appoints Robert R. Ruffolo, Ph.D., to Board of Directors

Retrieved on: 
Mardi, août 24, 2021
Glaucoma, Discoverer, Oxidative stress, Diabetic retinopathy, Heart, Foundation Fighting Blindness, Ohio, Trial of the century, GLOBE, Carvedilol, Board of directors, B cell, Dobutamine, Research, Usher syndrome, Senior, Board, Foundation, Retinitis pigmentosa, Ohio State University, Patient, CEO, Cataract, GSK, Wyeth, Pharmaceutical industry

He was President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008.

Key Points: 
  • He was President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008.
  • Prior to Wyeth, Dr. Ruffolo was Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years.
  • Dr. Ruffolo currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals.
  • Nacuity Pharmaceuticals, Inc., is a Fort Worth, Texas-based clinical stage biopharmaceutical company focused on advancing treatments for ocular conditions involving oxidative stress.